Change in the statistical considerations and sample size of the study as follows: Statistical considerations A sample size of 3300 (1650 per group) for arm [A] (i.e. rtPA dose) will provide (i) >90% power to detect non-inferiority (relative margin 14% [i.e. relative risk 1.14], absolute margin rate 6.5%) of low-dose rtPA on the primary outcome (one-sided α = 0.025), and (ii) ≥80% power to detect plausible 40% reductions in risks of sICH with low-dose rtPA (2-sided α = 0.05) with 5% drop-out. A sample size of 2304 (1152 per group) for arm [B] (i.e. BP lowering intensities) will provide ≥90% power to detect superiority of intensive BP lowering on the primary outcome and any ICH(2-sided α = 0.05) with 5% drop-out. Given overlap of approximately 800 patients in the combined arms [A] and [B], an expected total of 4800 patients will participate in the study. A total of 100+ sites are required, most in Asia (approximately 60 sites) and Australia/New Zealand, Europe (approximately 40 sites), and South America (approximately 30 sites), to achieve the sample of 4800 patients ([50%] from Asia) over 4 years (av. 6 patients per site per year). Also, amendment to the BP target for the BP arm of the study as follows: Systolic BP ≥150 mmHg; no definite indication or contraindication to rapid intensive BP lowering to 130-140mmHg systolic target. Other administrative changes

Addition of: Reason for this Protocol amendment from version 4.0 to version 5.0: The rtPA dose arm of the study addressing questions (1) and (3) concluded with a publication of the results in May 2016. The BP intensity arm of the study is ongoing, and the protocol has been modified to reflect changes. Change of secondary aims: Other secondary aims are to define the effects of the treatments on symptomatic and any ICH; good outcome (mRS 0-1), death or major disability (mRS 3-6); separately on death and disability (mRS 3-5); Explaining that the arm A of low- vs standard-dose rtPA has now closed;